Minocycline accelerates hypoxia-inducible factor-1 alpha degradation and inhibits hypoxia-induced neovasculogenesis through prolyl hydroxylase, von Hippel-Lindau-dependent pathway

Archives of Toxicology

Volumn 88, Issue 3, 2014, Pages 659-671

  Li, Ching Hao ^a   Liao, Po Lin ^b   Yang, Ya Ting ^b   Huang, Shih Hsuan ^b,c   Lin, Cheng Hui ^c   Cheng, Yu Wen ^c   Kang, Jaw Jou ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hypoxia inducible factor 1 alpha; Minocycline; Neovasculogenesis; Prolyl hydroxylase; Von Hippel Lindau

Indexed keywords

GELATINASE A; GLUCOSE TRANSPORTER 1; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MINOCYCLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN KINASE B; SLC2A1 PROTEIN, HUMAN; VASCULOTROPIN C; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

CELL HYPOXIA; CELL LINE; CELL MOTION; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL HYPOXIA; CELL LINE; CELL MOVEMENT; GLUCOSE TRANSPORTER TYPE 1; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MATRIX METALLOPROTEINASE 2; MINOCYCLINE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROLYL HYDROXYLASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84894572787     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-013-1175-5     Document Type: Article

References (53)

1. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia inducible factor. J Biol Chem 279:38458-38465
2. Barliya T, Mandel M, Livnat T, Weinberger D, Lavie G (2011) Degradation of HIF-1alpha under hypoxia combined with induction of hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy. PLoS One 26:e22849
3. Basini G, Baioni L, Bussolati S, Grolli S, Kramer LH, Wagner GF, Grasselli F (2010) Expression and localization of stanniocalcin 1 in swine ovary. Gen Comp Endocrinol 166:404-408
4. Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, Papandreou CN, Liakos P (2012) Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med 90:45-54
5. Bettany JT, Peet NM, Wolowacz RG, Skerry TM, Grabowski PS (2000) Tetracyclines induce apoptosis in osteoclasts. Bone 27:75-80
6. Chen CH, Tsai PS, Huang CJ (2013) Minocycline ameliorates lung and liver dysfunction in a rodent model of hemorrhagic shock/resuscitation plus abdominal compartment syndrome. J Surg Res 180:301-309
7. Chen-Scarabelli C, Saravolatz L, Latchman D, Knight R, Gardin J (2004) Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. J Am Coll Cardiol 43:865-874
8. Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232-260
9. Chu HC, Lin YL, Sytwu HK, Lin SH, Liao CL, Chao YC (2005) Effects of minocycline on Fas-mediated fulminant hepatitis in mice. Br J Pharmacol 144:275-282
10. DeClerck K, Elble RC (2010) The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci 15:213-225
11. Ganji PN, Park W, Wen J, Mahaseth H, Landry J, Farris AB, Willingham F, Sullivan PS, Proia DA, El-Hariry I, Taliaferro-Smith L, Diaz R, El-Rayes BF (2013) Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Angiogenesis 16:903-917
12. Garcia-Martinez EM, Sanz-Blasco S, Karachitos A, Bandez MJ, Fernandez-Gomez FJ, Perez-Alvarez S, de Mera RM, Jordan MJ, Aguirre N, Galindo MF, Villalobos C, Navarro A, Kmita H, Jordán J (2010) Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol 79:239-250
13. Griffin MO, Ceballos G, Villarreal FJ (2011) Tetracycline compounds with nonantimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res 63:102-107
14. Huang CL, Lee YC, Yang YC, Kuo TY, Huang NK (2012) Minocycline prevents paraquat-induced cell death through attenuating endoplasmic reticulum stress and mitochondrial dysfunction. Toxicol Lett 209:203-210
15. Iwai K, Yamanaka K, Kamura T, Minato N, Conaway RC, Conaway JW, Klausner RD, Pause A (1999) Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96:12436-12441
16. Jiang BH, Liu LZ (2009) PI3 K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102:19-65
17. Jung JE, Kim HS, Lee CS, Shin YJ, Kim YN, Kang GH, Kim TY, Juhnn YS, Kim SJ, Park JW, Ye SK, Chung MH (2008) STAT3 inhibits the degradation of HIF-1α by pVHL-mediated ubiquitination. Exp Mol Med 40:479-485
18. Kaelin WG (2009) Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115(10 Suppl):2262-2272
19. Kamat CD, Green DE, Warnke L, Thorpe JE, Ceriello A, Ihnat MA (2007) Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett 249:209-219
20. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG Jr, Elledge SJ, Conaway RC, Harper JW, Conaway JW (1999) Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657-661
21. Kong X, Lin Z, Liang D, Fath D, Sang N (2006) Histone deacetylase inhibitors induce VHL and ubiquitin independent proteasomal degradation of hypoxia inducible factor 1α. Mol Cell Biol 26:2019-2028
22. Lee SJ, No YR, Dang DT, Dang LH, Yang VW, Shim H, Yun CC (2013) Regulation of hypoxia-inducible factor 1α (HIF-1α) by lysophosphatidic acid is dependent on interplay between p53 and Kruppel-like factor 5. J Biol Chem 288:25244-25253
23. Li CH, Cheng YW, Hsu YT, Hsu YJ, Liao PL, Kang JJ (2010) Benzo[a]pyrene inhibits angiogenic factors-induced alphavbeta3 integrin expression, neovasculogenesis, and angiogenesis in human umbilical vein endothelial cells. Toxicol Sci 118:544-553
24. Lin CH, Li CH, Liao PL, Tse LS, Huang WK, Cheng HW, Cheng YW (2013) Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway. Br J Pharmacol 168:920-931
25. Liu YV, Baek JH, Zhang H, Diez R, Cole RN (2007) RACK1 competes with HSP90 for binding to HIF-1α and is required for O2-independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol Cell 25:207-217
26. Liu WT, Lin CH, Hsiao M, Gean PW (2011) Minocycline inhibits the growth of glioma by inducing autophagy. Autophagy 7:166-175
27. Liu Y, Bernauer AM, Yingling CM, Belinsky SA (2012a) HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis 33:1187-1192
28. Liu Z, Yuan Q, Zhang X, Xiong C, Xue P, Ruan J (2012b) RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR. Cancer Chemother Pharmacol 69:1633-1640
29. Lu N, Hui H, Yang H, Zhao K, Chen Y, You QD, Guo QL (2013) Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway. Eur J Pharm Sci 49:220-226
30. Manalo DJ, Baek JH, Buehler PW, Struble E, Abraham B, Alayash AI (2011) Inactivation of prolyl hydroxylase domain (PHD) protein by epigallocatechin (EGCG) stabilizes hypoxia-inducible factor (HIF-1α) and induces hepcidin (Hamp) in rat kidney. Biochem Biophys Res Commun 416:421-426
31. Mizuno S, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, Voelkel NF, Ishizaki T (2011) p53 gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol 300:L753-L761
32. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, Cordenonsi M, Piccolo S (2012) SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 487:380-384
33. Mucaj V, Shay JES, Simon MC (2012) Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol 95:464-470
34. Newman B, Liu Y, Lee HF, Sun D, Wang Y (2012) HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. Cancer Res 72:4551-4561
35. Noble W, Garwood CJ, Hanger DP (2009) Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion 3:78-83
36. Ossola B, Lantto TA, Puttonen KA, Tuominen RK, Raasmaja A, Männistö PT (2012) Minocycline protects SH-SY5Y cells from 6-hydroxydopamine by inhibiting both caspase-dependent and -independent programmed cell death. J Neurosci Res 90:682-690
37. Pang T, Wang J, Benicky J, Saavedra JM (2012) Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition. Biochim Biophys Acta 1820:503-510
38. Pourgholami MH, Mekkawy AH, Badar S, Morris DL (2012) Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol 125:433-440
39. Saivin S, Houin G (1988) Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15:355-366
40. Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258-265
41. Sermeus A, Michiels C (2011) Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2:e164
42. Seukeran DC, Eady EA, Cunliffe WJ (1997) Benefit-risk assessment of acne therapies. Lancet 349:1251-1252
43. Smith TG, Talbot NP (2010) Prolyl hydroxylases and therapeutics. Antioxid Redox Signal 12:431-433
44. Smith C, Woods CG, Woods MJ (1984) Absorption of minocycline. J Antimicrob Chemother 13:93
45. Song D, Li LS, Heaton-Johnson KJ, Arsenault PR, Master SR, Lee FS (2013a) Prolyl hydroxylase domain protein 2 (PHD2) binds a Pro-Xaa-Leu-Glu motif, linking it to the heat shock protein 90 pathway. J Biol Chem 288:9662-9674
46. Song X, Yao J, Wang F, Zhou M, Zhou Y, Wang H, Wei L, Zhao L, Li Z, Lu N, Guo Q (2013b) Wogonin inhibits tumor angiogenesis via degradation of HIF-1α protein. Toxicol Appl Pharmacol 271:144-155
47. Suk K (2004) Minocycline suppresses hypoxic activation of rodent microglia in culture. Neurosci Lett 366:167-171
48. Szeto GL, Pomerantz JL, Graham DRM, Clements JE (2011) Minocycline suppresses activation of nuclear factor of activated T cells 1 (NFAT1) in human CD4 T cells. J Biol Chem 286:11275-11282
49. Takeda M, Kawaguchi M, Kumatoriya T, Horiuchi T, Watanabe K, Inoue S, Konishi N, Furuya H (2011) Effects of minocycline on hind-limb motor function and gray and white matter injury after spinal cord ischemia in rats. Spine 36:1919-1924
50. Tao R, Kim SH, Honbo N, Karliner JS, Alano CC (2010) Minocycline protects cardiacmyocytes against simulated ischemia-reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 56:659-668
51. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z (2004) Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 279:19948-19954
52. Xue J, Lv DD, Jiao S, Zhao W, Li X, Sun H, Yan B, Fan L, Hu RG, Fang J (2012) pVHL mediates K63-linked ubiquitination of nCLU. PLoS One 7:e35848
53. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D, Lowenstein CJ (2010) P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 107:6334-6339